CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
Isebia KT, Mostert B, Belderbos BPS, Buck SAJ, Helmijr JCA, Kraan J, Beaufort CM, Van MN, Oomen-de Hoop E, Sieuwerts AM, van IJcken WFJ, van den Hout-van Vroonhoven MCGN, Brouwer RWW, Oole E, Hamberg P, Haberkorn BCM, Helgason HH, de Wit R, Sleijfer S, Mathijssen RHJ, Martens JWM, Jansen MPHM, van Riet J, Lolkema MP.
Isebia KT, et al. Among authors: buck saj.
Eur J Cancer. 2022 Dec;177:33-44. doi: 10.1016/j.ejca.2022.09.032. Epub 2022 Oct 6.
Eur J Cancer. 2022.
PMID: 36323051
Free article.